Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Apitox Add-on Therapy for Improving Disability and QOL in MS Patients

NCT03710655 is registered in ClinicalTrials.gov with Apimeds, Inc. as lead sponsor.

NCT NCT03710655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03710655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Apitox Add-on Therapy for Improving Disability and QOL in MS Patients
Lead sponsor
Apimeds, Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
April 30, 2019
Completion date
November 30, 2019
Enrollment
468 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis